|
|
Mucopolysaccharidosis
|
|
Mucopolysaccharidosis
[an error occurred while processing this directive]
BioMarin to Host Research and Development Day on Tuesday, December ... Nov 22, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ...
- PR Newswire (press release),
BioMarin Announces Third Quarter 2005 Financial Results Nov 1, 2005
...blind portion of the trial in late March of 2006." Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I ...
- PR Newswire (press release),
BioMarin Announces Third Quarter 2005 Financial Results Nov 1, 2005
Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased 95 percent to ...
- PR Newswire (press release),
Why Iraq is a Hideously Expensive Distraction, Part II: "The ... Oct 24, 2005
We spend almost no money researching a cure for mucopolysaccharidosis, which usually kills its victims by age 25 but only affects about 200 people nationwide. ...
- Blogcritics.org,
SHIRE PRESENTS POSITIVE RESULTS OF HUNTER SYNDROME PIVOTAL ... Oct 28, 2005
Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare, life threatening, genetic disorder with no available treatment. ...
- ITNews,
Shire Presents Positive Results of Hunter Syndrome Pivotal ... Oct 28, 2005
About Hunter Syndrome and Idursulfase Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare, life threatening, genetic disorder with no ...
- PR Newswire (press release),
Hunter Syndrome Sep 16, 2005
Mucopolysaccharidosis Type II, called Hunter syndrome, is an inherited disorder in which an enzyme, iduronate-2-sulfatase (I2S), is deficient. ...
- rarediseases.about.com
One stolen puppy doomed Sep 26, 2005
Massey researchers say Beau is a carrier of mucopolysaccharidosis, also known as storage disease, or MP3a, which is present in humans under the name San ...
- Stuff.co.nz
BioMarin to Present at the 2005 UBS Global Life Science Conference Sep 20, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ...
- PharmaLive.com (press release)
BioMarin Announces Positive Opinion for Naglazyme From European ... Sep 15, 2005
Marketing Authorization Application for Naglazyme(TM) (galsulfase) an investigational enzyme replacement therapy for treatment of mucopolysaccharidosis VI (MPS ...
- PR Newswire (press release)
Committee for Medicinal Products for Human Use Summary of Opinion ... Sep 16, 2005
...concentrate for solution for infusion intended for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS ...
- PharmaLive.com (press release)
Head, Neck Infections Due to Dental Cysts More Common than ... Sep 21, 2005
Dentigerous cysts are usually solitary with multiple cysts reported on occasion in association with syndromes such as mucopolysaccharidosis and basal cell ...
- Newswise (press release)
The best day of my life! Sep 22, 2005
Oliver, from Drighlington, Leeds, suffers from the rare genetic condition mucopolysaccharidosis (MPS) VI, also known as Maroteaux-Lamy Syndrome. ...
- Leeds Today
BioMarin Announces Reduction of Orapred Sales ForceJul 5, 2005
Additionally, BioMarin will continue to market Naglazyme for mucopolysaccharidosis VI (MPS VI) in the United States and to conduct a disease awareness campaign ...
- Yahoo News
BioMarin lowers Orapred revenue guidanceJul 5, 2005
...revenue outlook for another drug -- an enzyme-replacement therapy called Aldurazyme that treats a rare genetic disease called mucopolysaccharidosis I. BioMarin ...
- BusinessWeek
BioMarin Announces Public Offering of 8,500,000 Shares of Common ...Jul 14, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ...
- Yahoo News
BioMarin lowers sales forecastJul 7, 2005
BioMarin raised its revenue outlook for Aldurazyme, which treats a rare genetic disease called mucopolysaccharidosis I, to between $70 million and $75 million ...
- Marin Independent-Journal
Highlights of rising and falling US stocksJul 6, 2005
...company said it now expects sales of Aldurazyme, its treatment for mucopolysaccharidosis, in the range of $70 million to $75 million, up from a prior estimate ...
- Investor's Business Daily (subscription)
BioMarin Reducing Orapred Sales Force, Blames GenericsJul 7, 2005
The "good news of the day," Bienaime said, is that Aldurazyme for mucopolysaccharidosis I, which had been expected to sell between $60 million and $66 million ...
- BioWorld Online (subscription)
From orphan to blockbuster?Jul 8, 2005
...up $0.16 to $7.55, Research) have co-developed Aldurazyme, a treatment for Mucopolysaccharidosis 1, or MPS 1, a genetic disease the prevents enzyme production. ...
- CNN
Treatments now available for lysosomal storage diseasesJul 1, 2005
...before irreversible damage has occurred. Mucopolysaccharidosis type I (MPS I) also is a recessive condition. It typically presents in ...
- AAP News (subscription)
This page is updated on a monthly basis if relevant articles are available. If you are looking for further information on
Mucopolysaccharidosis
you may want to try searching the Internet using the Google search box below.
|
|
|
